Related Experiment Video

Updated: May 22, 2025

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

11.8K

Reply to: Reflections on the HORSE Trial: Hyperthermic Intraperitoneal Chemotherapy, BRCA Status, and Clinical

Anna Fagotti1, Rita Trozzi1, Diana Giannarelli1

  • 1Anna Fagotti, MD, PhD and Rita Trozzi, MD, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy, Università Cattolica del Sacro Cuore, Rome, Italy; Diana Giannarelli, PhD, MSc, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy; and Giovanni Scambia, MD, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome, Italy, Università Cattolica del Sacro Cuore, Rome, Italy.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|March 14, 2025
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Author Spotlight: Computing the Effects of a Local Radiofrequency Hyperthermia Intervention on Tumor Biomechanics10:23

Author Spotlight: Computing the Effects of a Local Radiofrequency Hyperthermia Intervention on Tumor Biomechanics

Published on: December 1, 2023

337
Protocol for Long Duration Whole Body Hyperthermia in Mice07:56

Protocol for Long Duration Whole Body Hyperthermia in Mice

Published on: August 25, 2012

11.5K

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K